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INTRODUCTION
Treatment-resistant hypertension (TRH) is 
defined by the American Heart Association 
and European Society of Cardiology (AHA/
ESC) as high blood pressure (BP) in patients 
taking three or more differing groups of 
antihypertensive medications (one of which 
must be a diuretic-type medication), or 
patients who are taking four or more 
antihypertensive medications regardless of 
type and blood pressure level.1,2 BP levels 
need to be adapted to specific morbidity 
(for example, diabetes), ambulatory blood 
pressure measurement (ABPM) must 
exclude white-coat hypertension (WCH), 
doses should be the optimal tolerated 
for each particular medication, and both 
non-adherence and lifestyle should 
be examined.1,3–5 When these pseudo-
resistance issues6 have not yet been ruled 
out as a potential cause for the ongoing 
high BP, the term apparent treatment-
resistant hypertension (aTRH) is used. 
Apparent TRH can be considered as an 
overdiagnosis — a concept that is gaining 
increasing attention.7 True treatment-
resistant hypertension (tTRH) estimates will 
clearly be lower. 
A recent meta-analysis8 in various 
hypertensive populations suggests a 
prevalence of aTRH of 13.7% for 20 
observational cohorts, and of 16.3% for 
four randomised trials.9 However, the 
individual studies were very heterogeneous 
(I2 >90%) with prevalence estimates varying 
between 4% and 25%.10,11 There were many 
reasons for this. First, the definition of aTRH 
varied, as some simply included those on 
three medications without specifying the 
need, as required, for a diuretic,12 whereas 
others ignored those on four or more 
medications with a normal BP.4 Second, 
many studies used large health Insurance 
databases12 or BP registries,4 and this 
can create a selection bias. Furthermore, 
some population studies are based on 
questionnaire and survey approaches 
only.10,13 Third, a general cut-off was often 
used to define hypertension (for example, 
≥140/90 mmHg), without considering 
individual morbidities, such as diabetes 
or kidney disease, which require a lower 
threshold (130/80 mmHg). It is now also 
accepted that patients >80 years should 
have a higher threshold of 150/80 mmHg.14 
Fourth, ABPM is essential to rule out WCH,15 
but in most studies manual BP readings are 
solely used. Additional criticism includes the 
lack of consideration of optimal medication 
dosing and patient adherence.16
The authors therefore conducted a cross-
sectional study of the prevalence of TRH in 
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Abstract
Background
To confirm treatment-resistant hypertension 
(TRH), ambulatory blood pressure measurement 
(ABPM) must exclude white-coat hypertension 
(WCH), three or more medications should be 
prescribed at the optimal doses tolerated, 
and non-adherence and lifestyle should be 
examined. Most previous studies have not 
adequately considered pseudo-resistance 
and merely provide an apparent TRH (aTRH) 
prevalence figure. 
Aim
To conduct a cross-sectional study of the 
prevalence of aTRH in general practice, and 
then consider pseudo-resistance and morbidity. 
Design and setting
With support, 16 practices ran an anatomical 
therapeutic chemical (ATC) drug search, 
identifying patients on any possible hypertensive 
medications, and then a search of individual 
patients’ electronic records took place. 
Method
ABPM was used to rule out WCH. The World 
Health Organization-defined daily dosing 
guidelines determined adequate dosing. 
Adherence was defined as whether patients 
requested nine or more repeat monthly 
prescriptions within the past year.
Results
Sixteen practices participated (n = 50 172), and 
646 patients had aTRH. Dosing was adequate 
in 19% of patients, 84% were adherent to 
medications, as defined by prescription refill, 
and 43% had ever had an ABPM. Using a 
BP cut-off of 140/90 mmHg, the prevalence 
of aTRH was 9% (95% confidence interval 
[CI] = 9.0 to 10.0). Consideration of pseudo-
resistance further reduced prevalence rates to 
3% (95% CI = 3.0 to 4.0).
Conclusion
Reviewing individual patient records results in 
a lower estimate of prevalence of TRH than has 
been previously reported. Further consideration 
for individual patients of pseudo-resistance 
additionally lowers these estimates, and may be 
all that is required for management in the vast 
majority of cases.
Keywords
adherence; cross-sectional studies; dosing; 
hypertension; primary care; pseudo-
resistances.
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general practice, using the correct AHA/
ESC definition, and with consideration of 
individual patient morbidity, and the three 
key aspects of pseudo-resistance — WCH, 
inadequate dosing, and non-adherence.
METHOD
Forty general practices in the university-
affiliated research network, WestREN, 
representative of the Irish population, were 
invited to participate.17 All used the same 
practice software system (Socrates®) and 
the International Classification for Primary 
Care (ICPC-2) coding of chronic diseases. 
Data were collected between May 2015 and 
October 2016, and this work fulfilled the 
Irish Medical Council requirement for GPs 
to conduct an annual audit. 
Ireland does not have universal 
registration with a GP. Almost 45% of 
the population is registered through the 
primary care reimbursement service 
(PCRS), with the remainder being described 
as private patients and able to see any 
GP.18 All patients aged >80 years and those 
below defined income levels (<€500 [£444] 
gross per week for a single person; €900 
[£798] gross per week for a couple) are 
registered with the PCRS. The authors 
therefore included in the cross-sectional 
sample all PCRS patients and those private 
patients who had attended the practice in 
the past year. 
The authors supported each practice in 
fulfilling the annual audit requirements of 
the Irish Medical Council. Each practice ran 
a standard anatomical therapeutic chemical 
(ATC) drug search, identifying patients on 
any possible hypertensive medications as 
defined by the British National Formulary.19 
The record of each individual patient who 
was reported as being on one or more 
hypertensive medication was reviewed and 
it was determined if they were hypertensive 
or not, and what hypertensive medications 
they were currently receiving. Two 
researchers supported each practice in this 
process to ensure consistency. 
Patients were described as having 
diabetes if they had ICPC codes T89 (diabetes 
insulin dependent) or T90 (diabetes non-
insulin dependent), or were taking insulin 
or oral hypoglycaemic agents. Patients 
were described as having chronic kidney 
disease (CKD) if an estimated glomerular 
filtration rate (eGFR) <60 mls/min/1.73 m2 
was recorded. Patients were described as 
having cardiac failure if they had ICPC code 
K77 or were noted to have this condition on 
hospital correspondence. This figure would 
only include those with an initial secondary 
care diagnosis of heart failure.
The following BP thresholds were used 
for those on three or more appropriate 
medications, and the latest recorded 
manual clinic reading was the parameter 
used:
• manual office BP for patients <80 years: 
≥140/90 mmHg;
• manual office BP for patients >80 years: 
≥150/80 mmHg;
• manual office BP for patients with 
diabetes or chronic kidney disease: 
≥130/80 mmHg; and
• 24-hour ABPM (daytime mean 
with a minimum of 14 BP readings): 
≥135/85 mmHg.
WCH was a concern, and those with 
elevated clinic BP readings but normal 
ABPM reports within the previous 6 months, 
without significant medication changes, 
were excluded at initial discovery stage.
The World Health Organization-defined 
daily dosing (WHO-DDD) guidelines were 
used to determine whether adequate dosing 
was achieved.20 The DDD is the assumed 
average maintenance dose per day for a 
drug, used for its main indication, in adults. 
Egan et al adopted a slightly different 
approach, as they sought to determine the 
numbers of patients who were receiving, 
for each medication, diuretics apart, at 
least half the maximum dose.5 The authors 
present both approaches.
Adherence to antihypertensive 
medications was determined by prescription 
refill data. Patients requesting nine or more 
repeat monthly prescriptions within the past 
year were deemed adherent. Prescriptions 
are mainly dispensed quarterly, therefore 
the authors chose adherence as >75% 
How this fits in
Both the American Heart Association 
(2008) and the UK National Institute for 
Health and Care Excellence (2011) suggest 
the need for further research into the 
prevalence, prognosis, and management 
of people with treatment-resistant 
hypertension (TRH). Prevalence estimates 
typically lie between 10 and 30% of patients 
with hypertension. However, the three 
main factors of pseudo-resistance (non-
adherence, inadequate dosing, and white-
coat hypertension) are rarely examined. 
The authors have shown that these factors 
can be reviewed for individual patients, 
and physician evaluation may be all that is 
required in considering TRH in the majority 
of cases.
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prescriptions as opposed to the standard 
80%.
Statistical analysis
The authors used a fixed-effects (FE) model 
to estimate overall prevalence from the 
practices. The fixed-effects rather than 
random-effects (RE) was chosen given 
the cross-sectional design, the strict 
geographical inclusion criteria for practices, 
the similarity of patient covariates across 
practices, and the fact that estimation of 
prevalence of aTRH is the main objective 
rather than the analysis of heterogeneity. 
In fact, the results from both models were 
very similar (data available from the authors 
upon request). To account for adherence and 
adequate dosing, and various comorbidities, 
the authors performed regressions at the 
individual patient level on figures taken from 
the initial aTRH meta-analysis (Figure 1). 
Here, once again, the results from both 
models (FE and RE) were very similar. 
Statistics were analysed in R.
RESULTS
Sixteen practices participated, with an 
estimated total population of 50 172; of 
these, 31 157 were registered with the PCRS. 
Figure 2 provides a flow chart. Of the 2807 
patients on three or more medications, 646 
(9.6%) were deemed to have aTRH. Table 1 
illustrates the characteristics of those with 
aTRH. They were largely older patients 
(mean age 71 years) and male (53.7%), with 
PCRS eligibility (81.7%); 43% had ever had a 
previous ABPM. Figure 1 illustrates a meta-
analysis of prevalence by practice using a 
general threshold of ≥140/90 mmHg for all 
those without diabetes or chronic kidney 
disease who had a lower target BP of 
≥130/80 mmHg. The FE model suggests, 
with significant heterogeneity, a combined 
prevalence of 10% (95% confidence interval 
[CI] = 9.3 to 10.8%). 
Table 2 illustrates participants’ 
medication particulars. In all, 43.7% were 
on three medications only, with 56.9% 
taking one or more combined medication; 
83.9% appeared to be adherent, having had 
nine or more monthly prescriptions printed 
in the last 12 months. According to WHO-
DDD guidelines, 19% achieved adequate  
Total number of PCRS
registered and private patients:
50 172
Total identified on at least one 
hypertensive medication and as 
having hypertension on individual 
patient record review: 
6691
Excluded as prescribed two or less hypertensive medications: 3884, and
recorded as ever on  three or more hypertensive medications: 2807
Further exclusions:
Normal BP (manual or ABPM within 6 months if available): 425
No longer on three medications/or three medications and no diuretic: 1675 
No BP recording: 61
Apparent TRH: 646 (9.6%)
Figure 2. Flow chart of patients. ABPM = ambulatory 
blood pressure measurement. BP = blood pressure. 
PCRS = primary care reimbursement service. 








































































































































Figure 1. Meta-analysis of prevalence of aTRH by 
practice. aTRH = apparent treatment-resistant 
hypertension. CI = confidence interval. 
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dosing for each hypertensive medication, 
whereas 67.9% achieved adequate dosing 
when a parameter of >50% maximum 
dose in all medications, diuretics apart, 
is used. A nine-practice subset showed 
93% of patients with TRH were on a stable 
medication regimen for ≥3 months at the 
study onset. 
Table 3 describes dosing according to 
drug class. Renin–angiotensin–aldosterone 
system (RAAS) drugs had high levels of 
adequate dosing — ACE-inhibitors (93%) 
and angiotensin receptor blockers (95%) 
— in comparison with beta-blockers (31%) 
and thiazides (43%). The most common 
thiazide drug was hydrochlorthiazide 
(56% of all thiazide medications), which 
is frequently found in combination drugs. 
Mineralocorticoid antagonists were rarely 
used (7%).
Table 4 illustrates the FE meta-analysis 
of prevalence of aTRH hypertension in the 
cohort, after parameters for morbidity, age, 




The authors have found that reviewing 
individual general practice patient records 
results in a lower estimate of the prevalence 
of TRH than has generally been previously 
reported.8 This lower prevalence estimate 
is consistent with a recent estimate of 
6.5% from an analysis of the electronic 
health records from the UK Clinical Practice 
Datalink in Primary Care.21 Consideration 
for individual patients of additional criteria 
such as morbidity, dosing, exclusion of WCH, 
and adherence lowers these estimates 
even more. This suggests that TRH is an 
uncommon condition in general practice 
and use of ABPM, adequate dosing, and 
maximising adherence may be all that is 
required to manage the vast majority of 
cases. It could be argued that optimising 
doses in patients with aTRH may not lead 
to improvements for all, as many patients 
may have tried more suitable doses and 
had medication side effects-appropriate 
inaction. The authors accept this point. 
Table 1. Characteristics of patients with apparent treatment-resistant 
hypertension (n = 646)
Mean age (SD), years 71.1 (12.2)
Sex — female, n (%) 299 (46.3)
PCRS eligibility, n (%) 528 (81.7)
Diabetes, n (%) 237 (36.7)
Chronic kidney disease, n (%) 256 (40.0)
Cardiac failure, n (%) 88 (13.6)
Mean systolic clinic BP (SD), mmHg 142.1 (18.0) 
Mean diastolic clinic BP (SD), mmHg 78.1 (11.9)
Have ever had an ABPM, n (%) 276 (42.7)
Elevated ABPM (past 6 months, n = 74) 
 Mean daytime systolic ABPM (SD), mmHg 147.9 (21.5) 
 Mean daytime diastolic ABPM (SD), mmHg	 81.4 (14.8)
ABPM = ambulatory blood pressure measurement. BP = blood pressure. PCRS = primary care reimbursement 
service. SD = standard deviation.
Table 2. Medications of patients with apparent treatment-resistant 
hypertension (n = 646)
Mean number of hypertensive medications (SD) 3.7 (0.7)
On three hypertensive medications only, n (%)  282 (43.7)
Prescribed one or more combined medication, n (%) 368 (56.9)
Adequate WHO-DDD requirements for each hypertensive medication, n (%) 123 (19.0)
At least half recommended dosing for all medications (not diuretics), n (%) 439 (67.9)
Nine monthly PCRS prescriptions printed in the past 12 months, n (%) 542 (83.9)
PCRS = primary care reimbursement service. SD = standard deviation. WHO-DDD = World Health Organization-
defined daily dosing. 
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However, Gil-Guillen et al suggest that 
physician inertia to up-dose is a significant 
problem (70% of the time).22 The WHO-DDD 
guidelines were used to determine whether 
adequate dosing was achieved.20 Egan et al 
adopted a different approach, as they sought 
to determine the numbers of patients who 
were receiving, for each medication, apart 
from diuretics, at least half the maximum 
dose.5 This of course had a lower threshold 
for adequate dosing and a greater number 
of patients were deemed to be optimally 
dosed. It could be argued that the WHO 
daily defined dose for many of the more side 
effect-prone drugs, such as beta-blockers 
and thiazide diuretics, are too stringent. 
Many older patients do not tolerate such 
doses and are therefore rarely escalated 
to these levels for fear of significant side 
effects such as falls. Indeed data presented 
in Table 3, where RAAS, calcium channel 
blockers (CCBs), and alpha-blockers each 
achieve adequate WHO dosing in excess 
of 90%, suggest practitioners are adopting 
this pragmatic approach. The authors also 
note that improving dosing may not actually 
affect BP levels, but it is hard to quantify 
this.23 
The authors had anticipated that 
the outcome of this study would be to 
refer a significant number of patients for 
specialist opinion. This did not materialise, 
which suggests that perhaps TRH is 
overdiagnosed.
Strengths and limitations
In their systematic review, Achelrod et al 
identified a number of important limitations 
in studies reviewing the prevalence of 
resistant hypertension.8 An important 
contribution of the present study is how 
the authors have addressed these, using 
the AHA/ESC definition. He highlighted 
that the sampling frames used were 
often limited to those of convenience, 
referral centres, or specific health plans, 
with often a focus on high-risk patients. 
Reliance on large electronic insurance 
databases may result in the inclusion 
of more affluent patients. These factors 
constitute a source of selection bias and 
limited external validity. The authors have 
followed his recommendation in developing 
a prospective survey of a ‘clustered sample 
of participants from the general treated 
hypertensive population’. Also highlighted 
was the failure of observational studies to 
consider adherence and WCH. The authors 
have applied both the WHO-DDD guidelines 
and those of Egan et al 5 to determine 
whether adequate dosing was achieved. 
Recent ABPM results, where available, 
were used to exclude WCH at the initial 
patient discovery stage.
Limitations of this study include the 
use of 16 practices from one geographical 
region with an overwhelmingly white-
Table 3. Dosing according to drug class of patients with apparent 
treatment-resistant hypertension (n = 646) 
 Patients  Patients Patients adequately 
 on drug on drug dosed per class as per  
Medication group, n (%)  class, n (%)  WHO-DDD, n (%)
Diuretics 614 (95)
Thiazides  424 (65) 181 (43)
Loop  235 (36) 150 (64)
Potassium sparing  50 (8) 1 (2)
Mineralocorticoid antagonists  48 (7)  5 (10)
Renin–angiotensin–aldosterone	system	(RAAS)	 614 (95)
ACE-inhibitors  286 (44) 267 (93)
Angiotensin receptor blockers  320 (49) 305 (95)
Direct renin inhibitors  5 (1) 5 (100)
HR	reducers	 440 (68)
Beta-blockers  412 (63) 130 (31)
Calcium channel blockers —   41 (5) 11 (27)	
non dihydropyridines
CCB-DHP 440 (68)  
Calcium channel blockers — dihydropyridines  429 (68) 424 (99)
Vasodilators 129 (20)  
Alpha-blockers  127 (19) 124 (98)
Other vasodilators  3 (1) 0 (0)
Centrally	acting 2 (<1)
Centrally acting drugs  2 (1) 0 (0)
ACE = angiotensin-converting enzyme. CCB-DHP = calcium channel blockers — non-dihydropyridines. 
HR = heart rate. WHO-DDD = World Health Organization-defined daily dosing.
Table 4. Fixed-effects meta-analysis of apparent treatment-resistant 
hypertension according to additional criteria
 Prevalence  
Analysis estimate (95% CI) I2
Applying a threshold of 140/90 mmHg to all patients 0.09 (0.09 to 0.10) 0.76
And  
Applying a threshold of 130/80 mmHg for patients with diabetes or 0.10 (0.09 to 0.11) 0.74 
chronic kidney disease
And  
Applying a threshold of 150/80 mmHg for patients >80 years 0.09 (0.08 to 0.10) 0.76 
regardless of morbidity
And  
Applying a threshold of adequate dosing in all medications (WHO-DDD) 0.04 (0.04 to 0.05) 0.83
And  
Applying a threshold of adequate adherence (>75% prescriptions) 0.03 (0.03 to 0.04) 0.80
CI = confidence interval. WHO-DDD = World Health Organization-defined daily dosing. I 2 is the percentage of 
variance in the meta-analysis that is attributable to study heterogeneity.
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European population; the labour-intensive 
approach of individual patient record review 
necessitated this approach. The lack of 
universal registration or a unique health 
identifier in Ireland posed difficulties in 
determining a population denominator. 
Retaining only those private patients who 
had attended in the past year is clearly 
an arbitrary but, the authors believe, 
pragmatic decision. It may overestimate 
the levels of adherence. Like most other 
similar studies, the authors were unable 
to report exercise or dietary patterns. The 
definition of CKD was one, rather than two, 
eGFR readings of <60 mls/ min/1.73 m2. 
This would overestimate CKD prevalence, 
which in turn will overestimate TRH. The 
diagnosis of heart failure is a pragmatic 
one; future studies may choose to use echo 
criteria, which are increasingly available in 
primary care.
Comparison with existing literature
The operability of the AHA/ESC definition of 
resistant hypertension is difficult in routine 
practice. Even after reviewing individual 
general practice records, it is difficult to 
establish whether the dosing levels were the 
maximal tolerated. In addition, the routine 
standardised recording of lifestyle factors, 
such as diet and exercise, is not reliable. 
As a third issue, definitions should perhaps 
also include guidance about the duration of 
treatment in order for patients to qualify as 
having TRH (that is, ≥3 months stable on the 
requisite medications). Consideration could 
be given to developing a version of the AHA/
ESC definition that can be easily applied and 
audited in routine general practice.
Holmqvist described in a Swedish 
registry-based cohort study of 48 
practices the prevalence of TRH in 53 090 
hypertensive patients. Applying the AHA/
ESC definition, with consideration of 
adherence only, found a prevalence of 
17%.24 They excluded all patients whose 
proportion of days with pharmacy refills 
was <80% as not having TRH. The level of 
morbidity (for example, diabetes) and type of 
medication used in this contemporaneous 
Swedish group is very similar to this one. 
Mineralocorticoid antagonists were used in 
8% of Swedish patients, and 7% of Irish. The 
AHA guidelines2 emphasise the role that 
these drugs can play in the management 
of primary aldosteronism in patients with 
resistant hypertension.2 However, they 
require close monitoring and these data 
suggest that GPs are preferring, as a fourth 
agent, alpha-blockers. The impact of this 
strategy on patient outcomes requires 
evaluation. Daugherty et al conducted a 
key retrospective cohort study of 23 912 
patients with hypertension enrolled in two 
US health plans between 2002 and 2006.12 
A prevalence of 16% was determined — 
as with Holmqvist. However, consideration 
of dosing or WCH was not performed. In 
comparison with the Irish and Swedish 
groups, RAAS and alpha-blockers were 
less frequently used, at 69% and 10%, 
respectively. The use of mineralocorticoid 
antagonists was not reported. National 
variations in drug group usage patterns 
may provide accessible longitudinal 
observational data of combined drug 
class efficacy for patients with resistant 
hypertension.
Implications for research and practice
The authors have shown that reviewing 
individual general practice patient records 
is feasible and results in lower estimates 
of the prevalence of TRH. It also facilitates 
consideration of key pseudo-resistance 
factors, such as morbidity, dosing, 
exclusion of WCH, and adherence. RAAS 
drugs and alpha-blockers are most likely to 
achieve adequate doses. Future research, 
as suggested by Daugherty,12 Sarafidis,16 
and Achelrod8 is to develop, using this 
individual-based methodology, a larger 
community-based cohort of patients with 
apparent resistant hypertension to assess 
prognosis in routine practice, ideally with 
consideration of diet and exercise.
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